Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Decoding Pemafibrate: A Comprehensive Study of its R&D Trends
Drug Insights
4 min read
Decoding Pemafibrate: A Comprehensive Study of its R&D Trends
7 September 2023
This article summarized the latest R&D progress of Pemafibrate, the Mechanism of Action for Pemafibrate, and the drug target R&D trends for Pemafibrate.
Read →
Specific Nucleotide Sequence Searching and Finding
Bio Sequence
3 min read
Specific Nucleotide Sequence Searching and Finding
7 September 2023
Is it sufficient to solely search for nucleotide sequences when searching for a specific nucleotide sequence? Certainly not.
Read →
InvIOs starts a new clinical trial of innovative cell therapy APN401 for solid tumors
Latest Hotspot
4 min read
InvIOs starts a new clinical trial of innovative cell therapy APN401 for solid tumors
7 September 2023
InvIOs GmbH revealed today that it has launched patient enrollment for a Phase 1b trial of its innovative autologous cell therapy, APN401, focusing on solid tumor patients.
Read →
The PCSK9 inhibitor is set to trigger a fierce competition in the hyperlipidemia market?
The PCSK9 inhibitor is set to trigger a fierce competition in the hyperlipidemia market?
7 September 2023
Hypercholesterolemia refers to a condition in which the cholesterol level in the blood is abnormally elevated.
Read →
Inventory of Relay Pipeline and Eli Lilly's Acquisition of Kv1.3 Blockers
Advanced Tech.
8 min read
Inventory of Relay Pipeline and Eli Lilly's Acquisition of Kv1.3 Blockers
6 September 2023
Relay Therapeutics is a well-known drug discovery company in recent years, characterized by computational chemistry, with three drugs in its pipeline all from D.E. Shaw.
Read →
Deep Scientific Insights on Nalbuphine Hydrochloride's R&D Progress
Drug Insights
6 min read
Deep Scientific Insights on Nalbuphine Hydrochloride's R&D Progress
6 September 2023
Nalbuphine Hydrochloride is a small molecule drug that targets both the κ opioid receptor and μ opioid receptor.
Read →
EU Commission Approves Pfizer's ABRYSVO™ for RSV Protection in Infants, Elderly via Maternal Vaccination
Latest Hotspot
4 min read
EU Commission Approves Pfizer's ABRYSVO™ for RSV Protection in Infants, Elderly via Maternal Vaccination
6 September 2023
The European Union Commission has approved Pfizer's ABRYSVO™ to protect infants and the elderly from Respiratory Syncytial Virus infections via maternal vaccination.
Read →
Step-by-Step Guide on How to Search for Homologous Sequences of a Specific Gene
Bio Sequence
2 min read
Step-by-Step Guide on How to Search for Homologous Sequences of a Specific Gene
6 September 2023
Homology is a qualitative concept where we determine whether two sequences are homologous or not. However, the similarity between homologous sequences can be measured using techniques such as sequence alignment. One popular method for aligning sequences is using BLAST.
Read →
An Overview of Bristol Myers Squibb’s Pipeline | R&D Progress
R&D Pipeline
5 min read
An Overview of Bristol Myers Squibb’s Pipeline | R&D Progress
6 September 2023
Bristol Myers Squibb Co. is a pharmaceutical organization that was founded in 1887 and is headquartered in New York, United States.
Read →
Rallybio Unveils Phase 1 Data for Single Ascending Dose of RLYB116, a Novel Subcutaneous Complement Component 5 Inhibitor
Latest Hotspot
3 min read
Rallybio Unveils Phase 1 Data for Single Ascending Dose of RLYB116, a Novel Subcutaneous Complement Component 5 Inhibitor
6 September 2023
RLYB116, a potential long-acting solution, is a subcutaneously administered C5 inhibitor which is currently being developed for managing patients with complement-mediated diseases.
Read →
An In-depth Analysis of Luliconazole's R&D Progress
Drug Insights
5 min read
An In-depth Analysis of Luliconazole's R&D Progress
6 September 2023
Luliconazole is a small molecule drug that falls under the therapeutic areas of Infectious Diseases and Skin and Musculoskeletal Diseases. It primarily targets fungal CYP51A1.
Read →
A Retrieval Scheme for Any Combination of Antibodies Light Chains, Heavy Chains, and CDR
Bio Sequence
2 min read
A Retrieval Scheme for Any Combination of Antibodies Light Chains, Heavy Chains, and CDR
6 September 2023
Patsnap Bio Sequence Database can achieve the retrieval of antibody light and heavy chains, CDR sequence, and any CDR combination.
Read →